MARKET

NVCT

NVCT

Nuvectis Pharma, Inc.
NASDAQ
18.53
-10.01
-35.07%
Opening 11:04 06/30 EDT
OPEN
20.83
PREV CLOSE
28.53
HIGH
21.24
LOW
18.50
VOLUME
1.65M
TURNOVER
--
52 WEEK HIGH
29.28
52 WEEK LOW
5.55
MARKET CAP
491.39M
P/E (TTM)
-14.1900
1D
5D
1M
3M
1Y
5Y
1D
BUZZ-U.S. STOCKS ON THE MOVE-Oklo, Fortune Brands, Air Products
Reuters · 3h ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 4h ago
Concentrix Reports Downbeat Q2 Earnings, Joins Nuvectis Pharma, Vishay Intertechnology And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
Benzinga · 4h ago
BUZZ-Nuvectis Pharma tumbles on deep-discounted $100 mln share sale
Reuters · 4h ago
Why AeroVironment Shares Are Trading Higher By Over 21%; Here Are 20 Stocks Moving Premarket
Benzinga · 6h ago
Nuvectis Pharma 5M share Spot Secondary priced at $20.00
TipRanks · 6h ago
Biggest stock movers Tuesday: ABVX, AVAV, and more
Seeking Alpha · 7h ago
Reported Earlier, Nuvectis Pharma Prices $100M Public Offering Of 5M Common Shares At $20.00 Per Share
Benzinga · 9h ago
More
About NVCT
Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is developing two drug candidates: NXP800 and NXP900. NXP800 is a small molecule GCN2 activator that has been evaluated in a Phase Ib clinical trial for the treatment of platinum-resistant, ARID1a-mutated ovarian cancer, and it is exploring other development opportunities for NXP800. Chronic activation of GCN2 by NXP800 leads to cancer cell death. NXP900 is a targeted-therapy, small molecule drug candidate that inhibits the proto-oncogene c-Src (SRC) and YES1 kinases, which is in the Phase Ib program. SRC is aberrantly activated in many cancer types, including solid tumor cancers such as breast, colon, prostate, pancreatic and ovarian cancers. YES1 is a nonreceptor tyrosine kinase that belongs to the SRC family of kinases and controls multiple cancer signaling pathways.

Webull offers Nuvectis Pharma Inc stock information, including NASDAQ: NVCT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVCT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NVCT stock methods without spending real money on the virtual paper trading platform.